Q3 2024 EPS Estimates for Valneva SE (NASDAQ:VALN) Lifted by HC Wainwright

Valneva SE (NASDAQ:VALN) – HC Wainwright increased their Q3 2024 earnings per share estimates for Valneva in a research note issued to investors on Monday, July 22nd. HC Wainwright analyst E. White now anticipates that the company will post earnings per share of ($0.46) for the quarter, up from their prior forecast of ($0.49). HC Wainwright has a “Buy” rating and a $26.00 price target on the stock. The consensus estimate for Valneva’s current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Valneva’s Q4 2024 earnings at ($0.46) EPS, FY2024 earnings at ($0.50) EPS and FY2026 earnings at ($0.76) EPS.

Valneva (NASDAQ:VALN) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.89 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.12. The business had revenue of $35.56 million for the quarter, compared to analysts’ expectations of $95.80 million. Valneva had a negative net margin of 15.88% and a negative return on equity of 14.56%.

Valneva Price Performance

Shares of VALN opened at $7.25 on Thursday. The company has a 50 day moving average of $7.77 and a two-hundred day moving average of $7.90. The company has a quick ratio of 2.22, a current ratio of 2.64 and a debt-to-equity ratio of 0.84. Valneva has a twelve month low of $6.58 and a twelve month high of $15.28. The company has a market cap of $504.88 million, a price-to-earnings ratio of -17.68 and a beta of 2.20.

Institutional Trading of Valneva

An institutional investor recently raised its position in Valneva stock. General American Investors Co. Inc. raised its holdings in Valneva SE (NASDAQ:VALN) by 2.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 354,361 shares of the company’s stock after buying an additional 9,361 shares during the quarter. General American Investors Co. Inc. owned about 0.51% of Valneva worth $2,831,000 at the end of the most recent reporting period. 11.39% of the stock is currently owned by hedge funds and other institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.